NCT01797523 · OUTCOME

Progression-Free Survival (PFS)

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma · Source last updated 2026-07-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: 93 months

Analysis population: 54 participants were evaluable

Groups in this outcome

Rad-Let-Met

Everolimus 10 mg PO daily + Letrozole 2.5 mg PO daily + Metformin 500 mg PO twice daily on a 4 week schedule

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Rad-Let-Met	54

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Rad-Let-Met	5.7	Not reported	3	8.2	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
3
upper Limit
8.2
value
5.7

denoms

counts
group Id
OG000
value
54
units
Participants

dispersion Type

95% Confidence Interval

groups

description
Everolimus 10 mg PO daily + Letrozole 2.5 mg PO daily + Metformin 500 mg PO twice daily on a 4 week schedule
id
OG000
title
Rad-Let-Met

param Type

MEDIAN

population Description

54 participants were evaluable

reporting Status

POSTED

time Frame

93 months

title

Progression-Free Survival (PFS)

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice